ICP-B208 / InnoCare - LARVOL DELTA

Evaluation of ICP-B208 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=539 | Recruiting | Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Cancer • Oncology • Solid Tumor

InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China (GlobeNewswire)

Trial status • Solid Tumor

Evaluation of ICP-B208 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=539 | Not yet recruiting | Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

New P1/2 trial • Gastrointestinal Cancer • Oncology • Solid Tumor

InnoCare Pharma…announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to initiate a clinical trial of its novel CDH17 targeted ADC, ICP-B208 (GlobeNewswire) - "ICP-B208 is the second novel ADC to enter into clinical development by the Company’s in-house developed ADC platform..."

New trial • Gastrointestinal Cancer